Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $27.67, for a total value of $35,140.90. Following the completion of the sale, the director now owns 124,490 shares of the company’s stock, valued at $3,444,638.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $29.00 on Friday. The company has a market cap of $1.36 billion, a PE ratio of -15.03 and a beta of 1.10. The stock has a 50-day moving average of $24.08 and a 200-day moving average of $22.67. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. Analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the business. Quest Partners LLC raised its holdings in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the period. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics during the first quarter valued at $167,000. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at about $256,000. The Manufacturers Life Insurance Company purchased a new position in Enliven Therapeutics in the 2nd quarter worth approximately $322,000. Finally, Blackstone Inc. bought a new position in Enliven Therapeutics in the first quarter valued at $443,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.